Cefoxim 250 Tablet
Cefuroxime
250mg
Biochem Pharmaceuticals Industries Limited.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Cefoxim 250 Tablet is used for:
Pharyngitis, Acute otitis media, Lyme disease, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections,Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Urinary tract infections, Acute bacterial exacerbation of chronic bronchitis, Surgical Prophylaxis
Adult Dose
Pharyngitis/Tonsillitis
250 mg PO q12hr for 10 days
Acute Bacterial Maxillary Sinusitis
250 mg PO q12hr for 10 days
Acute Bacterial Exacerbations of Chronic Bronchitis
250-500 mg PO q12hr for 10 days
500-750 mg IV q8hr; switch to oral therapy as soon as clinically possible
Secondary Bacterial Infections of Acute Bronchitis
250-500 mg PO q12hr for 5-10 days
Uncomplicated Pneumonia
750 mg IV/IM q8hr
Uncomplicated Skin/Skin Structure Infections
250-500 mg PO q12hr for 10 days
750 mg IV/IM q8hr; switch to oral therapy as soon as clinically possible
Uncomplicated Urinary Tract Infections
125-250 mg PO q12hr for 7-10 days
750 mg IV/IM q8hr; switch to oral therapy as soon as clinically possible
Gonorrhea
Uncomplicated: 1 g PO once or 1.5 g IM once at 2 different sites with 1 g probenecid PO
Disseminated: 750 mg IV/IM q8hr
Early Lyme Disease
500 mg PO q12hr for 20 days
Severe or Complicated Infections
1.5 g IV/IM q8hr; may be administered q6hr in life-threatening situations
Oral
Susceptible infections
Adult: 250 mg bid.
Parenteral
Susceptible infections
Adult: 0.75 g 8 hrly, by deep IM or slow IV inj over 3-5 min or IV infusion, may increase up to 1.5 g 6-8 hrly in more severe infections.
Child Dose
Children: PO 20–30 mg/kg/day q12h
For bone and joint infections, up to 100 mg/kg/day
IV, IM 100–150 mg/kg/day q8h
Renal Dose
Renal impairment: Patients undergoing haemodialysis should receive an additional 750-mg dose after each dialysis; those undergoing continuous peritoneal dialysis may be given 750 mg bid.
CrCl (ml/min)
10-20 750 mg bid.
<10 750 mg once daily.
Administration
Tab: May be taken with or without food.
Oral susp: Should be taken with food.
IV Preparation
Direct injection: reconstitute in 8 mL (for 750-mg vial) or 16 mL (for 1.5-g vial) to obtain ~90 mg/mL solution
Infusion: Reconstitute in 100 mL SWI, D5W or NS to obtain 7.5 mg/mL (750-mg vial) or 15 mg/mL (1.5-g vial) solution
7.5 g bulk package not to be used for direct injection
IM Preparation
Reconstitute 750 mg in 3 mL SWI to obtain ~220 mg/mL solution
IV Administration
Direct injection: Inject directly into vein over 3-5 minutes or slowly into tubing of free-flowing compatible IV solution
Infusion: Infuse intermittently over 15-60 minutes
Contra Indications
Hypersensitivity to cephalosporins.
Precautions
Severe renal impairment; pregnancy, lactation; hypersensitivity to penicillins.
Lactation: Drug excreted in breast milk; use with caution
Pregnancy-Lactation
Interactions
May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.
Adverse Effects
Side effects of Cefuroxime :
>10%
Diarrhea (4-11%; depends on duration)
1-10%
Decreased hemoglobin or hematocrit (10%),Eosinophilia (7%),Nausea or vomiting (3-7%),Vaginitis (<5%),Transient rise in hepatic transaminases (2-4%),Diaper rash (3%),Increase in alkaline phosphatase (2%),Thrombophlebitis (2%),Increase in lactate dehydrogenase (1%)
<1%
Anemia,Cholestasis,Colitis,Dyspnea,Epidermal necrolysis,Increase in blood urea nitrogen (BUN) and creatinine,Jaundice,Nephritis,Prolonged prothrombin time (PT)/international normalized ratio (INR),Rash,Stevens-Johnson syndrome,Stomach cramps,Transient neutropenia and leukopenia,Urticaria
Potentially Fatal: Anaphylaxis, nephrotoxicity, pseudomembranous colitis.
Mechanism of Action
Cefuroxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Note
Cefoxim 250 250mg Tablet manufactured by Biochem Pharmaceuticals Industries Limited.. Its generic name is Cefuroxime. Cefoxim 250 is availble in Nepal.
Farmaco Nepal drug index information on Cefoxim 250 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.